ClinicalTrials.gg
RecruitingNCT07280429Updated Nov 5, 2026

Baduanjin Rehabilitation for Functional Restoration in ICI-Associated Myocarditis

An interventional study of rehabilitation protocol in Immune Checkpoint Inhibitors Related Myocarditis, sponsored by China-Japan Friendship Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by China-Japan Friendship Hospital · Not applicable, Interventional, and Treatment

How we know

Updated Nov 5, 2026Now RecruitingFirst site in China+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Myocarditis with a site in China — 10 open to participants now, 10 under way, 1 of them phase 3. Myocarditis · China.

Started
2026
with 1 other
No phase
Only one
of the 14
Registered
12th of 14
by date
Lead sponsor
1 of 14
China-Japan Friendship Hospital

Among the 14 studies in Myocarditis with a site in China, this one is one of 2 that started in 2026, is the only one with no phase, and was the 12th registered.

Myocarditis

175 studies on the registry are indexed under Myocarditis; 75 are open to participants now.

Browse Myocarditis studies →

Open to participants now

10 of the 14 studies in Myocarditis with a site in China are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 53 Myocarditis studies recruiting now, 32 (60%) set no upper age limit and 6 (11%) stop at 75 or younger; 15 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Myocarditis with a site in China, or all of them as a file.
02

Study summary

Immunotherapy has become a cornerstone in oncology; however, managing its associated adverse events poses a significant clinical challenge. Cardiotoxicity represents a major concern, among which myocarditis accounts for a considerable proportion. This condition is characterized by poor prognosis, highly heterogeneous outcomes, and a high prevalence of persistent cardiac dysfunction after the acute phase. The dual impact of myocardial injury and underlying malignancy severely compromises patients' quality of life. Currently, it remains unclear whether implementing rehabilitation strategies for this patient population can mitigate the aforementioned challenges. Therefore, we designed a randomized controlled trial to evaluate the efficacy and safety of a structured rehabilitation program for convalescent patients with ICIAM.

Read the detailed description

Eligible patients who are suitable for rehabilitation therapy and meet the TCM syndrome differentiation criteria of "Yangqi Deficiency with Internal Retention of Phlegm and Stasis" will be screened and undergo baseline assessments. Subsequently, they will be randomly assigned in a 1:1 ratio using block randomization to either the experimental group or the control group. The experimental group will receive a rehabilitation regimen consisting of Shengxian Quyu Decoction and specialized traditional Chinese exercise therapy, while the control group will receive conventional treatment only.The pharmacological rehabilitation intervention for the experimental group involves oral administration of Shengxian Quyu Decoction. The traditional exercise regimen is designed in accordance with the FITT principle (Frequency, Intensity, Time, Type) of exercise rehabilitation. Exercise modalities may include Baduanjin, with specific frequency, duration, and intensity tailored to individual patient conditions.The total rehabilitation period is 2 weeks. A follow-up assessment will be conducted at the end of the second week to document exercise adherence and evaluate physical examination findings, laboratory test results, TCM syndrome scores, quality of life, and Major Adverse Cardiovascular Events (MACE). Extended follow-up will continue through week 4 for MACE assessment.

03

Conditions studied

  • Immune Checkpoint Inhibitors Related Myocarditis

Browse trials for

04

Who can participate

The criteria were revised on the registry on Nov 5, 2026. See what changed

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 to 80 years, inclusive.
  • confirmed by cytology or histopathology.
  • Diagnosis of ICIAM following ICI therapy.
  • Assessed by the Multidisciplinary Team for Immune-Related Adverse Events as clinically recovered and entering the rehabilitation.
  • Meet TCM syndrome differentiation criteria for "Yangqi Deficiency with Internal Retention of Phlegm and Stasis."
  • score > 60, with a > 6 months.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of fulminant myocarditis or cardiac function of IV.
  • Clear evidence suggesting cardiac injury not attributable to ICIs.
  • Concurrent acute cardiovascular events or malignant arrhythmias.
  • Coexisting severe immune-related adverse events affecting other organ systems.
  • Associated severe systemic diseases, such as severe hepatic or renal insufficiency, or severe infection.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Rehab Arm

    The pharmacological rehabilitation protocol consists of oral administration of Shengxian Quyu Decoction. The traditional Chinese exercise rehabilitation protocol is designed following the FITT (Frequency, Intensity, Time, Type) principles of exercise therapy. Exercise modalities may include Baduanjin, with specific frequency, duration, and intensity tailored to each participant's actual condition. The total treatment period is 2 weeks.

    Other: rehabilitation protocol

  • No intervention
    Control Arm

    The control arm received conventional treatment.

Interventions

  • Otherrehabilitation protocol

    The intervention protocol comprised a pharmacological component (Shengxian Quyu therapy) and a traditional Chinese exercise rehabilitation component.The traditional Chinese exercise rehabilitation protocol is designed following the FITT (Frequency, Intensity, Time, Type) principles of exercise therapy. Exercise modalities may include Baduanjin, with specific frequency, duration, and intensity tailored to each participant's actual condition.

06

What researchers measure

Primary outcomes

  1. MACE

    Cardiovascular Death, Cardiac Arrest, Cardiogenic Shock, High-Grade Atrioventricular Block

    Time frame: 2 weeks

  2. NT-proBNP/BNP levels

    change in natriuretic peptide levels from baseline to Week 2

    Time frame: 2 weeks

  3. Change in EuroQol Visual Analogue Scale (EQ VAS) Score

    The EuroQol Visual Analogue Scale (EQ VAS), included in the EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire, assesses self-rated overall health status on a scale ranging from 0 (worst imaginable health) to 100 (best imaginable health). Higher scores indicate better self-rated health. The change in EQ VAS score from baseline to Week 2 will be assessed.

    Time frame: 2 weeks

Secondary outcomes

  1. MACE

    Rates of individual MACE components

    Time frame: 2 and 4 weeks

Other outcomes

  1. Exercise adherence

    Documenting patient exercise adherence

    Time frame: 2 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Dec 2026; primary completion for Jul 2028, 19 months later.

Start moved once since we started tracking on Sep 25, 2026: Jan 2026 → Dec 2026, on Nov 5, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2025
First posted
Dec 12, 2025
StartEst.
Dec 2026was Jan 2026
Primary completionEst.
Jul 31, 2028
CompletionEst.
Jul 31, 2028
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 5, 2026
Sites
1 site added — first site in China
Show site
  • China-Japan Friendship Hospital · Beijing, China
Nov 5, 2026
Start date
Jan 1, 2026→Dec 2026
Nov 5, 2026
Eligibility
6 inclusion criteria added, 1 removed; 5 exclusion criteria added, 1 removed
What changed in the criteria
Inclusion criteria
  • Removed①Aged 18 to 80 years, inclusive.②Malignancy confirmed by cytology or histopathology.③Diagnosis of ICIAM following ICI therapy.④Assessed by the Multidisciplinary Team for Immune-Related Adverse Events as clinically recovered and entering the rehabilitation.⑤Meet TCM syndrome differentiation criteria for "Yangqi Deficiency with Internal Retention of Phlegm and Stasis."⑥ KPS score > 60, with a life expectancy > 6 months.
  • AddedAged 18 to 80 years, inclusive.
  • AddedMalignancy confirmed by cytology or histopathology.
  • AddedDiagnosis of ICIAM following ICI therapy.
  • AddedAssessed by the Multidisciplinary Team for Immune-Related Adverse Events as clinically recovered and entering the rehabilitation.
  • AddedMeet TCM syndrome differentiation criteria for "Yangqi Deficiency with Internal Retention of Phlegm and Stasis."
  • AddedKPS score > 60, with a life expectancy > 6 months.
Exclusion criteria
  • Removed①Diagnosis of fulminant myocarditis or cardiac function of NYHA IV.②Clear evidence suggesting cardiac injury not attributable to ICIs.③Concurrent acute cardiovascular events or malignant arrhythmias.④Coexisting severe immune-related adverse events affecting other organ systems.⑤Associated severe systemic diseases, such as severe hepatic or renal insufficiency, or severe infection.
  • AddedDiagnosis of fulminant myocarditis or cardiac function of NYHA IV.
  • AddedClear evidence suggesting cardiac injury not attributable to ICIs.
  • AddedConcurrent acute cardiovascular events or malignant arrhythmias.
  • AddedCoexisting severe immune-related adverse events affecting other organ systems.
  • AddedAssociated severe systemic diseases, such as severe hepatic or renal insufficiency, or severe infection.
Nov 5, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore EQ-5DNow Change in EuroQol Visual Analogue Scale (EQ VAS) ScoreTime frame: 2 weeks
Nov 5, 2026
Title
ICIAM Rehabilitation Program Study: A Randomized Controlled Trial→Baduanjin Rehabilitation for Functional Restoration in ICI-Associated Myocarditis
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in China
    Show site
    • China-Japan Friendship Hospital · Beijing, China
    Start date Jan 1, 2026→Dec 2026
    Eligibility 6 inclusion criteria added, 1 removed; 5 exclusion criteria added, 1 removed
    What changed in the criteria
    Inclusion criteria
    • Removed①Aged 18 to 80 years, inclusive.②Malignancy confirmed by cytology or histopathology.③Diagnosis of ICIAM following ICI therapy.④Assessed by the Multidisciplinary Team for Immune-Related Adverse Events as clinically recovered and entering the rehabilitation.⑤Meet TCM syndrome differentiation criteria for "Yangqi Deficiency with Internal Retention of Phlegm and Stasis."⑥ KPS score > 60, with a life expectancy > 6 months.
    • AddedAged 18 to 80 years, inclusive.
    • AddedMalignancy confirmed by cytology or histopathology.
    • AddedDiagnosis of ICIAM following ICI therapy.
    • AddedAssessed by the Multidisciplinary Team for Immune-Related Adverse Events as clinically recovered and entering the rehabilitation.
    • AddedMeet TCM syndrome differentiation criteria for "Yangqi Deficiency with Internal Retention of Phlegm and Stasis."
    • AddedKPS score > 60, with a life expectancy > 6 months.
    Exclusion criteria
    • Removed①Diagnosis of fulminant myocarditis or cardiac function of NYHA IV.②Clear evidence suggesting cardiac injury not attributable to ICIs.③Concurrent acute cardiovascular events or malignant arrhythmias.④Coexisting severe immune-related adverse events affecting other organ systems.⑤Associated severe systemic diseases, such as severe hepatic or renal insufficiency, or severe infection.
    • AddedDiagnosis of fulminant myocarditis or cardiac function of NYHA IV.
    • AddedClear evidence suggesting cardiac injury not attributable to ICIs.
    • AddedConcurrent acute cardiovascular events or malignant arrhythmias.
    • AddedCoexisting severe immune-related adverse events affecting other organ systems.
    • AddedAssociated severe systemic diseases, such as severe hepatic or renal insufficiency, or severe infection.
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore EQ-5DNow Change in EuroQol Visual Analogue Scale (EQ VAS) ScoreTime frame: 2 weeks
    Title ICIAM Rehabilitation Program Study: A Randomized Controlled Trial→Baduanjin Rehabilitation for Functional Restoration in ICI-Associated Myocarditis
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07280429
Collaborators
Weifang Hospital of Traditional Chinese Medicine, Chinese Academy of Medical Sciences, Fuwai Hospital, Second Affiliated Hospital of Nanchang University
Responsible party
Jingyi Ren (Professor of medicine(Cardiology), Deputy Director of the Cardiology Department and Director of the Heart Failure Center, China-Japan Friendship Hospital) — Principal investigator
First posted
Dec 12, 2025
Start date
Dec 2026 (estimated)
Primary completion
Jul 31, 2028 (estimated)
Completion
Jul 31, 2028 (estimated)
Last update
Nov 5, 2026

Study contacts

Chengcheng L, Dr
Contact
lcc77983@126.com
010-84206809
Jingyi Ren, Professor
principal investigator · China-Japan Friendship Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion